Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label. Fexofenadine HCl and pseudoephredrine HCl extended-release tablets and ergocalciferol capsules represent the first two products launched in the U.S. by Winthrop U.S. under the Winthrop label with Prasco providing sales support and distribution services to Winthrop U.S. Prasco expects to begin shipping the products immediately. Specific financial terms of the agreements were not disclosed. "We are especially proud to expand our relationship with sanofi-aventis U.S., and we are certainly pleased to provide pharmacists and consumers with these authorized generic options," said Prasco Chief Executive Officer E. Thomas Arington. "Consumers and pharmacists can have confidence in their prescription drug choices, when they have the identical product, quality, reliability of supply and the identical experience that only the brand can provide." ALLEGRA-D and DRISDOL are registered trademarks of sanofi-aventis.